IMT504 a novel oligodeoxynucleotide immunotherapy, has shown robust results in numerous animal safety and efficacy models, as well as in humans. Most recently, exciting new data suggest that IMT504 could be the first ever-effective treatment for rabies. Mid-Atlantic BioTherapeutics is currently preparing to initiate three clinical trials using our clinical-stage compound IMT504.
IMT504 promises to be the first breakthrough therapy for rabies for which there are no effective therapies today. Virtually 100% of people with rabies infection die. There are more than 60,000 deaths per year from rabies with most cases in India, Asia and Africa.
Highly vulnerable patients, such as those with Ventilator-Associated Pneumonia (VAP) or significant burns, commonly have life-threatening antibiotic-resistant bacterial infections. IMT504 has shown impressive efficacy in multiple animal models against lethal Pseudomonas, which could translate to a new breakthrough, and effective treatment for patients. IMT504 could have a profound impact in terms of mortality and morbidity, hospitalization requirements, standard of care, quality of life, and health economics.
We project large commercial markets in economically-advanced countries for treatment of Pseudomonas infections in VAP patients and burn victims, and we see success in rabies as a gateway to accelerated FDA approval and rapid revenue.